The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials
Open accessAbstract
Amyotrophic lateral sclerosis (ALS), first described by Jean-Martin Charcot in the 1870s, is an age-related disorder that leads to degeneration of motor neurons. The disease begins focally in the central nervous system and then spreads relentlessly. The clinical diagnosis, defined by progressive signs and symptoms of upper and lower motor neuron dysfunction, is confirmed by electromyography. Additional testing excludes other conditions. The disease is heterogeneous, but most patients die of respiratory muscle weakness less than 3 years from symptom-onset. Like other age-related neurodegenerative diseases, ALS has genetic and environmental triggers. Of the five to 10% of cases that are inherited, mutations have been discovered for a high proportion. In addition to genetic factors, age, tobacco use, and athleticism may contribute to sporadic ALS, but important etiologies are unidentified for most patients. Complex pathophysiological processes, including mitochondrial dysfunction, aggregation of misfolded protein, oxidative stress, excitotoxicity, inflammation and apoptosis, involve both motor neurons and surrounding glial cells. There is clinical and pathological overlap with other neurodegenerative diseases, particularly frontotemporal dementia. The mechanisms leading to disease propagation in the brain are a current focus of research. To date, one medication, riluzole, licensed in 1996, has been proved to prolong survival in ALS. Numerous clinical trials have so far been unable to identify another neuroprotective agent. Researchers now aim to slow disease progression by targeting known pathophysiological pathways or genetic defects. Current approaches are directed at muscle proteins such as Nogo, energetic balance, cell replacement, and abnormal gene products resulting from mutations. Until better understanding of the causes and mechanisms underlying progression lead to more robust neuroprotective agents, symptomatic therapies can extend life and improve quality of life. Palliative care programs such as hospice give emotional and physical support to patients and families throughout much of the disease course.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062 · cited 1×
“Aging and Disease • Volume 4, Number 5, October 2013 298 The first mutation discovered was in the SOD1 gene on chromosome 21 [35].”
BackgroundEl Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433 · cited 3×
“Summary of Revised El Escorial Diagnostic Criteria for ALS [31]”
BackgroundMethodInfluentialA Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409
Mutations in the FUS/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis
Kwiatkowski, T. J., Bosco, D. A., LeClerc, A. L., Tamrazian, E., Vanderburg, C. R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E. J., Munsat, T., et al. (2009) · Science · doi:10.1126/science.1166066 · Cited by 2,553
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,233
Rowland, L. P., & Shneider, N. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442207 · Cited by 1,812
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V, Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,301
Decreased Glutamate Transport by the Brain and Spinal Cord in Amyotrophic Lateral Sclerosis
Rothstein, J. D., Martin, L. J., & Kuncl, R. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262204 · Cited by 1,177
Prognostic factors in ALS: A critical review
Chiò, A., Logroscino, G., Hardiman, O., Swingler, R., Mitchell, D., Beghi, E., Traynor, B. G., & On Behalf of the Eurals Consortium (2009) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482960802566824 · Cited by 1,172
Bourke, S. C., Tomlinson, M., Williams, T. L., Bullock, R. E., Shaw, P. J., & Gibson, G. J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70326-4 · Cited by 1,171
Cited by
Amyotrophic Lateral Sclerosis: A Focus on Disease Progression
Calvo, A. C., Manzano, R., Mendonça, D. M. F., Muñoz, M. J., Zaragoza, P., & Osta, R. (2014) · BioMed Research International · doi:10.1155/2014/925101 · Cited by 403
Altered Proteins in the Aging Brain
Elobeid, A., Libard, S., Leino, M., Popova, S. N., & Alafuzoff, I. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw002 · Cited by 202
Dupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182
Glia in the pathogenesis of neurodegenerative diseases
Verkhratsky, A., Parpura, V., Pekna, M., Pekny, M., & Sofroniew, M. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140107 · Cited by 141
Fan, W., Liang, C., Ou, M., Zou, T., Sun, F., Zhou, H., & Cui, L. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00090 · Cited by 116
Primary cilia and ciliary signaling pathways in aging and age-related brain disorders
Ma, R., Kutchy, N. A., Chen, L., Meigs, D. D., & Hu, G. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105607 · Cited by 114
Age-related neurodegenerative disease research needs aging models
Johnson, I. P. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00168 · Cited by 85
Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis
Jiang, Z., Wang, W., Perry, G., Zhu, X., & Wang, X. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0037-x · Cited by 66
“Introduction Amyotrophic lateral sclerosis (ALS), also referred to as Lou Gehrig’s disease, typically develops between 50 and 60 years of age and progresses rapidly with the average survival of less than 30 months after diagnosis or onset [1].”
BackgroundFilippini, T., Fiore, M., Tesauro, M., Malagoli, C., Consonni, M., Violi, F., Arcolin, E., Iacuzio, L., Oliveri Conti, G., Cristaldi, A., et al. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17030857 · Cited by 62
Information needs and information-seeking preferences of ALS patients and their carers
Abdulla, S., Vielhaber, S., Machts, J., Heinze, H.-J., Dengler, R., & Petri, S. (2014) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2014.932385 · Cited by 42
Huang, Z., Liu, Q., Peng, Y., Dai, J., Xie, Y., Chen, W., Long, S., Pei, Z., Su, H., & Yao, X. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00218 · Cited by 38
Metadata
- Authors
- AP-HP, H. D. L. P.-S., & Gordon, P.
- Venue
- Aging and Disease
- Publisher
- Aging and Disease
- Published
- 2013
- Volume
- 04
- Issue
- 05
- Pages
- 295-310
- ISSN
- 2152-5250 (ISSN-L)
- OpenAlex
- W2171305248
- Cited by
- 277
- References
- 135
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.